QIAGEN N.V.

QGEN · XNYS

CIK 1015820fmd_04MYJR0P3RFF2YG0HQFFJQZD9GManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2008 to Dec 31, 2025, 19 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	1,338	1,418	1,502	1,526	1,870	2,252	2,142	1,965	1,978	2,090
Cost of revenue	493	495	501	521	638	801	757	732	1,011	791
Gross profit	845	923	1,001	1,005	1,233	1,451	1,385	1,234	967	1,299
Realized investment gains (losses)	1	(1)	3	–	–	–	(6)	0	(0)	(1)
Provision for credit losses	–	–	–	–	1	2	6	0	(0)	0
Research and development	150	154	162	157	149	190	190	199	193	188
Selling, general and administrative	–	478	497	504	525	584	604	579	564	584
Total operating expenses	746	769	734	1,031	846	821	853	824	870	834
Operating income	99	153	267	(26)	386	630	531	410	98	466
Interest expense	39	50	67	74	71	54	58	53	44	33
Interest and investment income	7	11	21	22	10	10	33	79	68	64
Other non-operating income (expense)	(42)	(39)	(41)	(52)	53	(4)	(19)	20	23	24
Income before taxes	57	114	226	(78)	439	626	513	430	121	490
Income tax expense	(23)	74	35	(36)	80	113	89	89	38	65
Net income from continuing operations	80	40	190	(41)	359	513	423	341	84	425
Net income	80	40	190	(41)	359	513	423	341	84	425